Table 1.
Characteristics of cardiovascular adverse event reporting on androgen deprivation monotherapy (6,231) and combination therapy (1,793)
| No. Monotherapy (%) | No. Combination Therapy (%) | p Value | |
|---|---|---|---|
| Yrs age: | <0.001 | ||
| 18–39 | 91 (1.5) | 47 (2.6) | |
| 40–59 | 208 (3.3) | 71 (4.0) | |
| 60–79 | 3,603 (57.8) | 1,189 (66.3) | |
| ≥80 | 2,329 (37.4) | 486 (27.1) | |
| Year of reporting: | 0.09 | ||
| 2000–2013 | 1,821 (29.2) | 487 (27.2) | |
| 2014–2020 | 4,410 (70.8) | 1,306 (72.8) | |
| Reporting source: | <0.001 | ||
| Consumer | 7 (0.1) | 2 (0.1) | |
| Pharmaceutical company | 3,856 (61.9) | 1,358 (75.7) | |
| Health care professional | 2,167 (34.8) | 229 (12.8) | |
| Other | 201 (3.2) | 204 (11.4) | |
| Reaction type: | <0.001 | ||
| Serious | 5,526 (88.7) | 1,736 (96.8) | |
| Nonserious | 705 (11.3) | 57 (3.2) | |
| Hospitalized | 3,336 (53.5) | 1,192 (66.5) | <0.001 |
| Died | 1,292 (20.7) | 221 (12.3) | <0.001 |
Statistical testing was performed using Wilcoxon test for continuous variables and chi-squared test for categorical variables.